{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T06:15:27Z","timestamp":1786774527794,"version":"build-2736575974"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We conducted this meta-analysis to explore the tolerance of monotherapy with mirabegron (50\u200amg) on an overactive bladder, compared with a common dosage of anticholinergic agents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods:<\/jats:title>\n            <jats:p>A comprehensive search for all randomized controlled trials that evaluated the safety of mirabegron and anticholinergic agents on overactive bladder was performed, and we searched the Cochrane Central Register of Controlled trials databases, Pubmed, Embase, and relevant trials from 2013.02 to 2019.10.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eight studies included 5500 patients with treatment of monotherapy on overactive bladder were identified. The total number of treatment-emergent adverse events had no significantly difference between two monotherapies (RR\u200a=\u200a0.88 95%CI: 0.76\u20131.01; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.08); however, patients would have a better tolerance with mirabegron (50\u200amg) in adverse events of dry mouth (RR\u200a=\u200a0.42; 95%CI: 0.33\u20130.53; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.01) and tachycardia (RR\u200a=\u200a0.52; 95%CI: 0.29\u20130.94; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03); and there were no significant differences between two groups in hypertension (RR\u200a=\u200a1.02; 95%CI: 0.80\u20131.30; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.90), constipation (RR\u200a=\u200a0.91; 95%CI: 0.65\u20131.26; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.57), blurred vision (RR\u200a=\u200a1.03; 95%CI: 0.60\u20131.77; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a0.92), and urinary tract infection (RR\u200a=\u200a0.90; 95%CI: 0.70\u20131.16; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.41).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Treatment-emergent adverse events in patients with overactive bladder who underwent monotherapy of mirabegron (50\u200amg) or the anticholinergic agents had no significant differences, but mirabegron has a better tolerance in the aspect of dry mouth and tachycardia.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027469","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T22:26:19Z","timestamp":1637706379000},"page":"e27469","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Monotherapy with mirabegron had a better tolerance than the anticholinergic agents on overactive bladder"],"prefix":"10.1097","volume":"100","author":[{"given":"Wei","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5425-8216","authenticated-orcid":false,"given":"Yue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"issue":"(5 Suppl 2)","key":"R1-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.urology.2003.09.050","article-title":"Describing bladder storage function: overactive bladder syndrome and detrusor overactivity","volume":"62","author":"Abrams","year":"2003","journal-title":"Urology"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1046\/j.1464-410x.2001.02228.x","article-title":"How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study","volume":"87","author":"Milsom","year":"2001","journal-title":"BJU Int"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"e0175641","DOI":"10.1371\/journal.pone.0175641","article-title":"Analysis of the prevalence and associated factors of overactive bladder in adult Korean men","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.mayocp.2019.11.024","article-title":"Evaluation and treatment of overactive bladder in women","volume":"95","author":"Raju","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"R5-20250504","first-page":"682","article-title":"Epidemiology of over-active bladder (Oab) syndrome","volume":"155","author":"Eshkoli","year":"2016","journal-title":"Harefuah"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/nau.22429","article-title":"The prevalence and risk factors of OAB in middle-aged and old people in China","volume":"33","author":"Wen","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"733","DOI":"10.2165\/11592790-000000000-00000","article-title":"Safety and tolerability profiles of anticholinergic agents used for the treatment of overactive bladder","volume":"34","author":"Oefelein","year":"2011","journal-title":"Drug Saf"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.2147\/CIA.S252852","article-title":"Cognitive effects of anticholinergic load in women with overactive bladder","volume":"15","author":"Araklitis","year":"2020","journal-title":"Clin Interv Aging"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e026391","DOI":"10.1136\/bmjopen-2018-026391","article-title":"Association between cumulative anticholinergic burden and falls and fractures in patients with overactive bladder: US-based retrospective cohort study","volume":"9","author":"Szabo","year":"2019","journal-title":"BMJ Open"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s40265-018-0924-4","article-title":"Mirabegron: a review in overactive bladder syndrome","volume":"78","author":"Deeks","year":"2018","journal-title":"Drugs"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1590\/s1677-5538.ibju.2018.0518","article-title":"Efficacy and tolerability of mirabegron in female patients with overactive bladder symptoms after surgical treatment for stress urinary incontinence","volume":"45","author":"Ozkidik","year":"2019","journal-title":"Int Braz J Urol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/nau.23852","article-title":"Mirabegron as a treatment for overactive bladder symptoms in men (MIRACLE study): Efficacy and safety results from a multicenter, randomized, double-blind, placebo-controlled, parallel comparison phase IV study","volume":"38","author":"Shin","year":"2019","journal-title":"Neurourol Urodyn"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1016\/j.urology.2019.02.005","article-title":"The relative efficacy and safety of mirabegron and onabotulinumtoxin A in patients with overactive bladder who have previously been managed with an antimuscarinic: a network meta-analysis","volume":"127","author":"Lozano-Ortega","year":"2019","journal-title":"Urology"},{"key":"R14-20250504","first-page":"244","article-title":"Persistence in the treatment of overactive bladder (OAB) with Mirabegron in a multicentre clinical study","volume":"80","author":"Martan","year":"2015","journal-title":"Ceska gynekol"},{"issue":"(Suppl 3)","key":"R15-20250504","first-page":"S21","article-title":"Chapter 4: guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO)","volume":"33","author":"Nambiar","year":"2014","journal-title":"Neurourol Urodyn"},{"key":"R16-20250504","first-page":"ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database System Rev"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0197-2456(01)00147-7","article-title":"Quality in the reporting of randomized trials in surgery: is the Jadad scale reliable?","volume":"22","author":"Bhandari","year":"2001","journal-title":"Control Clin Trials"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e18802","DOI":"10.1097\/MD.0000000000018802","article-title":"The efficacy and safety of mirabegron on overactive bladder induced by benign prostatic hyperplasia in men receiving tamsulosin therapy: a systematic review and meta-analysis","volume":"99","author":"Su","year":"2020","journal-title":"Medicine"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/luts.12151","article-title":"Long-term persistence with mirabegron versus solifenacin in women with overactive bladder: prospective, randomized trial","volume":"10","author":"Kinjo","year":"2018","journal-title":"Lower Urinary Tract Symptoms"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2014.02.012","article-title":"Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony)","volume":"67","author":"Abrams","year":"2015","journal-title":"Eur Urol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.eururo.2018.05.005","article-title":"Long-term safety and efficacy of mirabegron and solifenacin in combination compared with monotherapy in patients with overactive bladder: a randomised, multicentre phase 3 study (SYNERGY II)","volume":"74","author":"Gratzke","year":"2018","journal-title":"Eur Urol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1111\/iju.13231","article-title":"Comparison of mirabegron and imidafenacin for efficacy and safety in Japanese female patients with overactive bladder: a randomized controlled trial (COMFORT study)","volume":"23","author":"Otsuka","year":"2016","journal-title":"Int J Urol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1177\/1756287215589250","article-title":"The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial","volume":"7","author":"Batista","year":"2015","journal-title":"Ther Adv Urol"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1111\/iju.12568","article-title":"Mirabegron 50\u200amg once-daily for the treatment of symptoms of overactive bladder: an overview of efficacy and tolerability over 12\u200aweeks and 1\u200ayear","volume":"21","author":"Chapple","year":"2014","journal-title":"Int J Urol"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1177\/1756287217702797","article-title":"Efficacy and safety of daily mirabegron 50\u200amg in male patients with overactive bladder: a critical analysis of five phase III studies","volume":"9","author":"Tubaro","year":"2017","journal-title":"Ther Adv Urol"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.pharmthera.2018.04.010","article-title":"Basic and clinical aspects of antimuscarinic agents used to treat overactive bladder","volume":"189","author":"Yamada","year":"2018","journal-title":"Pharmacol Ther"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1080\/13697137.2018.1552254","article-title":"Managing overactive bladder","volume":"22","author":"Robinson","year":"2019","journal-title":"Climacteric"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.urology.2008.04.038","article-title":"Effect of long-term oxybutynin administration on c-Fos expression in spinal neurons: inhibition of antimuscarinics on bladder afferents in conscious rats","volume":"73","author":"Haga","year":"2009","journal-title":"Urology"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/ijcp.12464","article-title":"Efficacy and safety of fesoterodine 8\u200amg in subjects with overactive bladder after a suboptimal response to tolterodine ER","volume":"68","author":"Kaplan","year":"2014","journal-title":"Int J Clin Pract"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:39:05Z","timestamp":1746333545000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027469"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":31,"journal-issue":{"issue":"41","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027469","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]},"assertion":[{"value":"2021-04-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}